Julie Lorent

1.6k total citations · 1 hit paper
15 papers, 973 citations indexed

About

Julie Lorent is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Julie Lorent has authored 15 papers receiving a total of 973 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Cancer Research. Recurrent topics in Julie Lorent's work include Breast Cancer Treatment Studies (3 papers), Cancer Cells and Metastasis (2 papers) and RNA modifications and cancer (2 papers). Julie Lorent is often cited by papers focused on Breast Cancer Treatment Studies (3 papers), Cancer Cells and Metastasis (2 papers) and RNA modifications and cancer (2 papers). Julie Lorent collaborates with scholars based in Sweden, Canada and United States. Julie Lorent's co-authors include Sandrine Marréaud, Iwona Skoneczna, Richard Sylvester, Joaquim Bellmunt, Maria De Santis, Sandra Collette, Pablo Maroto, Graham M. Mead, J. Martijn Kerst and Gedske Daugaard and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Blood.

In The Last Decade

Julie Lorent

15 papers receiving 960 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

2011 523 citations Maria De Santis, Joaquim Bellmunt et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julie Lorent Sweden	13	502	443	240	183	121	15	973
Valérie Cesson Switzerland	15	183 0.4×	307 0.7×	138 0.6×	514 2.8×	35 0.3×	27	709
Hiroto Matsui Japan	16	137 0.3×	379 0.9×	168 0.7×	228 1.2×	136 1.1×	66	707
C. O. Povlsen Denmark	11	215 0.4×	155 0.3×	145 0.6×	158 0.9×	76 0.6×	18	642
Toshiyuki Morisawa Japan	7	230 0.5×	147 0.3×	216 0.9×	232 1.3×	94 0.8×	18	641
Masaki Fukuyo Japan	17	135 0.3×	280 0.6×	431 1.8×	66 0.4×	205 1.7×	52	850
Clara Lubeseder–Martellato Germany	10	203 0.4×	358 0.8×	314 1.3×	160 0.9×	27 0.2×	13	660
Friederike Herbst Germany	12	56 0.1×	467 1.1×	545 2.3×	135 0.7×	52 0.4×	34	977
Christelle Harly United States	18	236 0.5×	431 1.0×	305 1.3×	1.5k 8.0×	29 0.2×	28	1.7k
Kouichiro Kawano Japan	17	87 0.2×	292 0.7×	337 1.4×	391 2.1×	39 0.3×	46	798
Nikki Levin United States	13	78 0.2×	267 0.6×	403 1.7×	24 0.1×	68 0.6×	34	811

Countries citing papers authored by Julie Lorent

Since Specialization

Citations

This map shows the geographic impact of Julie Lorent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie Lorent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie Lorent more than expected).

Fields of papers citing papers by Julie Lorent

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie Lorent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie Lorent. The network helps show where Julie Lorent may publish in the future.

Co-authorship network of co-authors of Julie Lorent

This figure shows the co-authorship network connecting the top 25 collaborators of Julie Lorent. A scholar is included among the top collaborators of Julie Lorent based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie Lorent. Julie Lorent is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Hunt, Matthew, Nuoqi Wang, Mónica S. Torres, et al.. (2024). Dantrolene corrects cellular disease features of Darier disease and may be a novel treatment. EMBO Molecular Medicine. 16(9). 1986–2001. 1 indexed citations

Rönnberg, Elin, Avinash Ravindran, Luca Mazzurana, et al.. (2023). Analysis of human lung mast cells by single cell RNA sequencing. Frontiers in Immunology. 14. 1151754–1151754. 5 indexed citations

Masvidal, Laìa, Julie Lorent, Tyson E. Graber, et al.. (2020). Translational profiling of macrophages infected with Leishmania donovani identifies mTOR- and eIF4A-sensitive immune-related transcripts. PLoS Pathogens. 16(6). e1008291–e1008291. 21 indexed citations

Oertlin, Christian, Julie Lorent, Carl Murie, et al.. (2019). Generally applicable transcriptome-wide analysis of translation using anota2seq. Nucleic Acids Research. 47(12). e70–e70. 49 indexed citations

Foukakis, Theodoros, John Lövrot, Alexios Matikas, et al.. (2018). Immune gene expression and response to chemotherapy in advanced breast cancer. British Journal of Cancer. 118(4). 480–488. 37 indexed citations

Lorent, Julie, Tyson E. Graber, Tania Charpentier, et al.. (2018). eIF4E-Binding Proteins 1 and 2 Limit Macrophage Anti-Inflammatory Responses through Translational Repression of IL-10 and Cyclooxygenase-2. The Journal of Immunology. 200(12). 4102–4116. 21 indexed citations

Lorent, Julie, Tyson E. Graber, Laìa Masvidal, et al.. (2018). The Protozoan Parasite Toxoplasma gondii Selectively Reprograms the Host Cell Translatome. Infection and Immunity. 86(9). 22 indexed citations

Liang, Shuo, Julie Lorent, Christian Oertlin, et al.. (2017). Polysome-profiling in small tissue samples. Nucleic Acids Research. 46(1). e3–e3. 46 indexed citations

Cajal, Santiago Ramón y, Claudia Capdevila, Javier Hernández‐Losa, et al.. (2017). Cancer as an ecomolecular disease and a neoplastic consortium. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1868(2). 484–499. 18 indexed citations

10.

Mao, Yumeng, Vincent van Hoef, Xiaonan Zhang, et al.. (2016). IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. Blood. 128(11). 1475–1489. 121 indexed citations

11.

Falato, Claudette, Nicholas P. Tobin, Julie Lorent, et al.. (2015). Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse. Molecular Oncology. 10(4). 517–525. 16 indexed citations

12.

Zhuang, Ting, Jian Zhu, Zhilun Li, et al.. (2015). p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells. Oncotarget. 6(41). 43853–43868. 42 indexed citations

13.

Falato, Claudette, Julie Lorent, Edneia Tani, et al.. (2014). Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer. Breast Cancer Research and Treatment. 147(2). 407–414. 22 indexed citations

14.

Mayer, Claus, Julie Lorent, & Graham Horgan. (2011). Exploratory Analysis of Multiple Omics Datasets Using the Adjusted RV Coefficient. Statistical Applications in Genetics and Molecular Biology. 10(1). Article 14–Article 14. 29 indexed citations

15.

Santis, Maria De, Joaquim Bellmunt, Graham M. Mead, et al.. (2011). Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986. Journal of Clinical Oncology. 30(2). 191–199. 523 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact